Drug Profile
OAP 189
Alternative Names: OAP189; PF-05212389; PF-5212389; WYE-155189Latest Information Update: 12 Nov 2012
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Obesity therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 09 Aug 2012 Discontinued - Phase-I for Obesity in USA (SC)
- 09 Aug 2012 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (SC)
- 11 Aug 2011 Pfizer completes a phase I trial in Type-2 diabetes mellitus in USA (NCT00970593)